The ‘Rapid Intervention with Glyceryl Trinitrate in Hypertensive Stroke Trial-2’ (RIGHT-2)

Funding body British Heart Foundation Clinical Study CS/14/4/30972.
Total funding £1,370,708
  • Professor Philip MW Bath, University of Nottingham
  • Professor Timothy England, University of Nottingham
  • Professor John Potter, University of East Anglia
  • Professor Christine Roffe, North Staffordshire Combined Healthcare Trust
  • Professor Alan Montgomery, University of Nottingham
  • Professor Thompson G Robinson, University of Leicester
  • Dr Chris I Price, University of Newcastle upon Tyne
  • Professor Joanne M Wardlaw, University of Edinburgh
  • Professor A Niroshan Siriwardena, University of Lincoln
Overarching aim The aim of the RIGHT2 trial was to assess the safety and efficacy of transdermal glyceryl trinitrate, a nitric oxide donor, in hyper-acute stroke in the context of a multicentre ambulance-based trial.
Objectives Primary objectives

  • To compare the difference between GTN and no GTN in death, disability, dependency, mood, cognition, and quality of life.

Secondary objectives

  • To assess the safety and tolerability of GTN in suspected ultra-acute stroke.
  • To compare the difference in peripheral blood pressure, central blood pressure, heart rate, and its derivatives between patients randomised to GTN or no GTN.
Methods Randomised controlled clinical trial


The most important expected outcomes of RIGHT2 will be to determine the difference between GTN and no GTN in death, disability, dependency, mood, cognition, and quality of life following stroke.
Outputs Publications: 

Bath PM, Scutt P, Anderson CS, Ankolekar A, Appleton JP, Berge E, Cala L, Dixon M, England TJ, Godolphin PJ, Havard D, Haywood L, Hepburn T, Krishnan K, Mair G, Montgomery AA, Muir K, Phillips SJ, Pocock S, Potter J, Price CI, Randall M, Robinson TG, Roffe C, Rothwell PM, Sandset EC, Sanossian N, Saver JL, Shone A, Siriwardena AN, Wardlaw JM, Woodhouse LJ, Venables G, Sprigg N et al (2019). Prehospital transdermal glyceryl trinitrate in patients with ultra-acute presumed stroke (RIGHT-2): an ambulance-based, randomised, sham-controlled, blinded, phase 3 trial. The Lancet (online first)

Conference presentations:


Impact Clinical-medical: a novel treatment for hyper-acute stroke which, if shown to be effective, will change management of stroke worldwide.

Economic: potential for reduction in costs of hospital treatment and long term health and social care from stroke.

Social: potential for prevention of long-term disability and suffering from stroke.


Leave a Reply

Your email address will not be published. Required fields are marked *